Drugs / BCT301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07301164 | Dec 2025 → Dec 2027 expected | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, idiopathic inflammatory myopathy +2 | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCT301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07301164 ↗ |
| Modality | Cell therapy | “CAR-iT (chemically induced T-cell) therapy derived from human chemically induced pluripotent stem cells (CiPSCs)” NCT07301164 ↗ |
| Target | CD19 | “CD19-targeted CAR-iT cell product” NCT07301164 ↗ |